Supriya Lifescience Q1 FY27 Revenue Jumps 31% YoY to ₹189.75 Crore
Supriya Lifescience reported Q1 FY27 revenue of ₹189.75 crore, a 31% YoY increase. EBITDA was ₹47.46 crore, and PAT was ₹24.04 crore. The company plans to launch new products in Anesthetic and ADHD segments.
The substantial revenue growth is a positive indicator of market demand and expansion. However, the decline in profitability margins requires careful monitoring and could impact investor sentiment. The company's strategic plans for new product launches and capacity expansion suggest potential for future improvement.
While revenue saw significant growth, profitability metrics like EBITDA and PAT declined year-over-year, indicating a mixed financial performance. The company's future growth plans provide a positive outlook, but the decrease in margins tempers the overall sentiment.
Supriya Lifescience Ltd. announced its unaudited financial results for the first quarter ended June 30, 2026. The company reported a significant year-over-year revenue growth of 30.8%, reaching ₹189.75 crore compared to ₹145.07 crore in the same period last year.
Despite the revenue increase, EBITDA for Q1 FY27 stood at ₹47.46 crore, a decrease from ₹51.70 crore in Q1 FY26, resulting in a lower EBITDA margin of 25.0% compared to 35.6%. Profit After Tax (PAT) also saw a decline, recording ₹24.04 crore in Q1 FY27 against ₹34.79 crore in Q1 FY26, with the PAT margin dropping to 12.7% from 24.0%.
The Anesthetic segment remained the largest contributor to revenue at 48%, followed by Vitamins at 17%. Geographically, Asia emerged as the largest market with 39% of revenue, while Europe contributed 35%. Exports constituted 81% of the total revenue.
The company highlighted the ongoing momentum in its product portfolio, with new contributions from a Cardiovascular product and strong demand for an ADHD product. A Liquid Anesthetic product has also been commercialized. Supriya Lifescience plans to launch approximately two new products each in the Anesthetic and ADHD segments within FY27.
Capacity utilization was at 70% for Q1 FY27. The Ambernath facility has commissioned its finished dosage manufacturing capabilities. The company continues to invest in R&D with 68+ scientists and aims to add 3-4 products annually. Dr. Satish Wagh, Executive Chairman, expressed confidence in sustained long-term growth driven by a strong export-oriented business and strategic investments.
What to do with a filing like this
Supriya Lifescience Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Supriya Lifescience Limited. Read the original for the full detail.